At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 642 enrolled
Drug / intervention
Carboplatin +3 moredrug
Likely dose
Paclitaxel 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer
In Brief
A Phase 3 clinical trial evaluating Carboplatin, Paclitaxel, and 2 other interventions for Non-small Cell Lung Cancer Metastatic. Completed, enrolled 642 participants across 4 sites in 3 countries.
Detailed Summary
The purpose of this research study is to compare the effectiveness and safety of ABP 215 against bevacizumab in men and women with advanced non-small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer Metastatic
CountriesAustralia, Bulgaria, United States
CollaboratorsActavis Inc.
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 2013
Enrollment StartNov 2013
Primary CompletionJul 2015
TodayJul 2026
First PostedOct 21, 2013
Enrollment StartNov 11, 2013
Primary CompletionJul 23, 2015
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 12.7 years ago
Interventions
Carboplatindrug
Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W
Paclitaxeldrug
Administered 200 mg/m² IV Q3W
ABP 215drug
Administered 15 mg/kg Q3W by IV infusion
Bevacizumabdrug
Administered 15 mg/kg Q3W by IV infusion